BCL2 AND p53: APOPTOSIS MARKERS OF BREAST CANCER IN HUMAN


  • V. Fulga State University of Medicine and Pharmacy “Nicolae Testemitanu”, Republic of Moldova

Abstract

BCL2 AND p53: APOPTOSIS MARKERS OF BREAST CANCER IN HUMAN

References

1. Callagy G.M., Pharoah P.D., Pinder S.E., et al. BCL2 is a prognostic marker in breast cancer independently of the Nottingham Prognostic Index. Clin Cancer Res 2006;12(8):2468–2475.



2. Yamashita H., Nishio M., Toyama T., et al. Coexistence of HER2 over-expression and p53 protein accumulation is a strong prognostic molecular marker in breast cancer. Breast Cancer Res. 2004;6:R24-30.



3. Honma N, Horii R, Ito Y, et al. Differences in clinical importance of Bcl-2 in breast cancer according to hormone receptors status or adjuvant endocrine therapy. BMC Cancer;15:698.



4. Schuler M., Green D.R. Transcription, apoptosis and p53: catch-22. Trends Genet. 2005; 21(3):182-7.



5. Arun B., Kilic G., Yen C., et al. Correlation of BCL2 and p53 expression in primary breast tumors and corresponding metastatic lymph nodes. Cancer 2003;98(12):2554–2559.



6. Ihemelandu C.U., Dewitty R.L. Jr, Leffall L.D. Jr, et al. Clinical significance of p53 and bcl-2 pro- tein coexpression phenotypes in molecular breast cancer subtyp es of pre-menopausal and post-menopausal African-American women. Am Surg. 2009;75(9):776-84



7. Pratt M.A.,, White D., Kushwaha N., et al. Cytoplasmic mutant p53 increases Bcl-2 expression in estrogen receptor-positive breast cancer cells. Apoptosis. 2007;12(4), 657–69.
Published
2017-12-29
How to Cite
Fulga, V. (2017). BCL2 AND p53: APOPTOSIS MARKERS OF BREAST CANCER IN HUMAN. Biological Markers in Fundamental and Clinical Medicine (scientific Journal), 1(4), 5-6. https://doi.org/10.29256/v.01.04.2017.escbm01
Section
Selected abstracts